




PHARMACEUTICAL 2021

Fulcrum Therapeutics Inc.
Rank 186 of 402





RealRate

PHARMACEUTICAL 2021

Fulcrum Therapeutics Inc. Rank 186 of 402



The relative strengths and weaknesses of Fulcrum Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Fulcrum Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 50% points. The greatest weakness of Fulcrum Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 36% points.

The company's Economic Capital Ratio, given in the ranking table, is 113%, being 66% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	119,510
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	26,725
Liabilities, Non-Current	0
Other Assets	1,670
Other Compr. Net Income	-2.0
Other Expenses	0
Other Liabilities	7,671
Other Net Income	792
Other Revenues	8,823
Property and Equipment	8,397
Research and Development	59,042
Selling, General and Administrative Expense	21,392

Output Variable	Value in 1000 USD
Assets	129,577
Liabilities	34,396
Expenses	80,434
Revenues	8,823
Stockholders Equity	95,181
Net Income	-70,819
Comprehensive Net Income	-70,820
Economic Capital Ratio	113%